CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies
Latest Information Update: 07 Mar 2023
At a glance
- Drugs Anti CD19 anti CD20 chimeric antigen receptor T cell therapy PersonGen BioTherapeutics (Primary)
- Indications Haematological malignancies
- Focus Therapeutic Use
- Sponsors PersonGen Biotherapeutics
- 14 Jan 2021 New trial record